Hansa Biopharma AB (HNSBF)
2.93
0.00 (0.00%)
USD |
OTCM |
Sep 20, 16:00
Hansa Biopharma Profit Margin (Quarterly): -605.6% for June 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -605.6% |
| March 31, 2024 | -390.5% |
| December 31, 2023 | -246.9% |
| September 30, 2023 | -1.10K% |
| June 30, 2023 | -685.3% |
| March 31, 2023 | -849.1% |
| December 31, 2022 | -483.2% |
| September 30, 2022 | -229.5% |
| June 30, 2022 | -644.3% |
| March 31, 2022 | -457.2% |
| December 31, 2021 | -1.06K% |
| September 30, 2021 | -3.00K% |
| June 30, 2021 | -2.92K% |
| March 31, 2021 | -1.16K% |
| December 31, 2020 | -2.76K% |
| September 30, 2020 | -16.06K% |
| June 30, 2020 | -15.93K% |
| March 31, 2020 | -10.55K% |
| December 31, 2019 | -9.21K% |
| September 30, 2019 | -14.46K% |
| June 30, 2019 | -13.92K% |
| Date | Value |
|---|---|
| March 31, 2019 | -7.90K% |
| December 31, 2018 | -5.86K% |
| September 30, 2018 | -12.70K% |
| June 30, 2018 | -6.53K% |
| March 31, 2018 | -7.91K% |
| December 31, 2017 | -4.84K% |
| September 30, 2017 | -5.53K% |
| June 30, 2017 | -6.52K% |
| March 31, 2017 | -4.25K% |
| December 31, 2016 | -6.18K% |
| September 30, 2016 | -2.97K% |
| June 30, 2016 | -5.66K% |
| March 31, 2016 | -3.40K% |
| December 31, 2015 | -1.08K% |
| September 30, 2015 | -2.63K% |
| June 30, 2015 | -4.25K% |
| March 31, 2015 | -278.8% |
| December 31, 2014 | -8.13K% |
| September 30, 2014 | |
| June 30, 2014 | -1.39K% |
| March 31, 2014 | -372.1% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-16.06K%
Minimum
Sep 2020
-229.5%
Maximum
Sep 2022
-4.14K%
Average
-1.08K%
Median
Profit Margin (Quarterly) Benchmarks
| Abliva AB | -- |
| Karolinska Development AB | -3.28K% |
| Calliditas Therapeutics AB | -8.48% |
| Oncopeptides AB | -1.45K% |
| BioInvent International AB | -2.98K% |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -74.22% |
| Return on Invested Capital | -104.8% |
| Gross Profit Margin (Quarterly) | -18.04% |
| Operating Margin (Quarterly) | -545.8% |
| Return on Net Operating Assets | -281.5% |